Friday, March 11, 2016

Business Briefing: Europe Investigates Safety of Gilead Leukemia Drug

European regulators have started a review into the safety of Gilead Sciences’ leukemia drug Zydelig over concerns about serious adverse events, including deaths.









No comments:

Post a Comment